Creative Medical Technology Holdings Inc CELZ

$0.95 +0.00 (0.50%)

Valuation

Market cap: 6,239,000
Revenue TTM: $10,000
Net income TTM: $-6,000,000
PE ratio: 0.00
Forward PE: —
Profit margin: -60,000.00%
Debt to equity: 0.00

Trading

Volume: 89,400
Avg volume: 8,615,246
Day's range: $0.92 – $0.97
Shares out: 6,593,000
Stochastic %K: 59%
Beta: 2.06
Analysts: Sell
Price target: $20.00

Price

Company profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Industry: Biotechnology
Sector: Healthcare
Phone: 480 399 2822
Website: https://www.creativemedicaltechnology.com
Address: 211 East Osborn Road, Phoenix, United States

Latest news

No headlines yet.

Stocktwits

FroNOBaggins Oct 2, 4:32 PM

$CELZ shareholders have funded this company for years. What have the different stakeholders received? • Shareholders: stock down ~99.99% since 2019, repeated dilution. • Warbington: ~$2.89M in disclosed compensation from 2019–2025. • Other executives/directors: ~$4.53M more. • Board/management authorized another 75 MILLION shares. • Warbington-controlled CAC. CELZ paid $200K + 1M CELZ shares to increase its BioDefense ownership from 60% to 80%. Yet BioDefense was described as using Creative Medical’s patented cell platform. The filing does not explain how CAC obtained its original 40% or what it contributed. And shareholders? We absorb the losses, dilution and financing risk. As a former bull and substantial shareholder I cannot even get a response to my questions. The IR email bounces, and follow-ups to management/board members have gone unanswered. Before shareholders fund more: Why did CAC own 40% of BioDefense, and what did CELZ shareholders receive in return? Where is the alignment?

0 replies

Veraton Oct 1, 9:26 PM

$CELZ how? Be so kind to give us your theory....

0 replies

popo12341 Oct 1, 9:22 PM

$CELZ Big spike to 1$ a second ago things are lining up

0 replies

YouVSYou Oct 1, 9:08 PM

$CELZ .92/.96 ww $SSM Fibonacci

0 replies

Veraton Sep 29, 5:51 PM

$CELZ clusterfuck

0 replies

FroNOBaggins Sep 29, 5:21 PM

$CELZ The Investor Relations email address published by the company is rejecting messages because the mailbox is full. I also called the telephone number displayed on the company website (480) 399-2822) under “Reach us directly” and received a recording stating that the wireless caller was unavailable. That same telephone number appears in the company's recent SEC filings. I am therefore unable to reach the company through either of the contact methods it provides to shareholders.

0 replies

FroNOBaggins Sep 29, 3:49 PM

$CELZ @CreativeMedical_IR Strategic partnerships for Olastrocel make sense. But this still does not address the governance questions shareholders are asking about BioDefense and Bionance. How did the CEO’s private company acquire 40% of BioDefense? What did it contribute? Why does Bionance give insiders separate economic upside while CELZ supplies most of the capital? How were these related-party arrangements independently reviewed? I’m still waiting for a response to my 9/23 email. The published IR address has also bounced my emails because the forwarding mailbox was full. The company account on StockTwits has not answered any of these questions. Why? Promotional communication is not a substitute for answering reasonable shareholder governance questions.

0 replies

CreativeMedical_IR Sep 29, 3:13 PM

As clinical programs advance, strategic partnerships can play a role in supporting later-stage development by providing additional resources, expertise and development capabilities. For $CELZ, evaluating potential strategic and partnering opportunities is part of Olastrocel’s stated development priorities as the ADAPT clinical dataset matures. This evaluation is one component of the broader strategy for supporting Olastrocel through its next stages of development.

0 replies